Mature tertiary lymphoid structures in lung adenocarcinoma are associated with better progression free survival

Abstract Introduction/Objective The presence of inducible lymphoid structures known as tertiary lymphoid structures in the tumor microenvironment has been shown to correlate with positive clinical outcome. However, the maturation states of lymphoid aggregates in lung adenocarcinoma are not completely understood. Methods/Case Report Seventy tumor samples from 69 patients diagnosed with lung adenocarcinoma (Stages I to III) between 2013 and 2015 were included in the study. The presence and maturation states of the lymphoid structures within the tumors were evaluated by conventional and 26 samples were further analyzed by multiplexed immunohistochemistry of formalin fixed paraffin embedded tissues and then quantified. Mature lymphoid follicles containing germinal centers were identified by the presence of CD21+ and BCL-6+ cells in an organized configuration within tight clusters of T and B cells. Results (if a Case Study enter NA) Samples with fully mature lymphoid structures (germinal centers) had larger tumors and higher disease stage. The number of mature lymphoid structures correlated with the total number of lymphoid aggregates present in the tumor microenvironment. Additionally, tumor samples with ≥10 mature lymphoid structures had more primary follicles. While there was no difference in overall survival, progression free survival was significantly longer in patients who had ≥10 mature lymphoid structures in comparison with patients who had <10 mature structures. Conclusion In conclusion, a spectrum of lymphoid aggregates in different stages of maturation are present in lung adenocarcinoma. An increase in the number of mature lymphoid structures may be associated with progression free survival in patients with lung adenocarcinoma.

Download Full-text

MA09.06 Mature Tertiary Lymphoid Structures in Lung Adenocarcinoma Are Associated With Better Progression Free Survival

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.156 ◽

2021 ◽

Vol 16 (10) ◽

pp. S912-S913

Author(s):

R. Obeng ◽

V. Parihar ◽

D. Alexis ◽

G. Sica

Keyword(s):

Lung Adenocarcinoma ◽

Progression Free Survival ◽

Free Survival ◽

Tertiary Lymphoid Structures ◽

Lymphoid Structures

Download Full-text

The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures

Frontiers in Immunology ◽

10.3389/fimmu.2021.694079 ◽

2021 ◽

Vol 12 ◽

Author(s):

Roger Li ◽

Anders Berglund ◽

Logan Zemp ◽

Jasreman Dhillon ◽

Ryan Putney ◽

...

Keyword(s):

Tumor Microenvironment ◽

Predictive Marker ◽

Immune Checkpoint Blockade ◽

Lymphoid Organ ◽

Predictors Of Response ◽

Tertiary Lymphoid Structures ◽

Lymphoid Structures ◽

Tumor Types ◽

Anti Tumor Activity ◽

Lymphoid Aggregates

There is emerging evidence that the adaptive anti-tumor activity may be orchestrated by secondary lymphoid organ-like aggregates residing in the tumor microenvironment. Known as tertiary lymphoid structures, these lymphoid aggregates serve as key outposts for lymphocyte recruitment, priming and activation. They have been linked to favorable outcomes in many tumor types, and more recently, have been shown to be effective predictors of response to immune checkpoint blockade. We have previously described a 12-chemokine (12-CK) transcriptional score which recapitulates an overwhelming enrichment for immune-related and inflammation-related genes in colorectal carcinoma. Subsequently, the 12-CK score was found to prognosticate favorable survival in multiple tumors types including melanoma, breast cancer, and bladder cancer. In the current study, we summarize the discovery and validation of the 12-CK score in various tumor types, its relationship to TLSs found within the tumor microenvironment, and explore its potential role as both a prognostic and predictive marker in the treatment of various cancers.

Download Full-text

Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status

BMC Cancer ◽

10.1186/s12885-021-07863-z ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xuejun He ◽

Jijun You ◽

Haibing Ding ◽

Zhisheng Zhang ◽

Lin Cui ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Target Therapy ◽

Vasculogenic Mimicry ◽

Therapy Response ◽

Progression Free Survival ◽

Egfr Mutations ◽

Line Treatment ◽

First Line ◽

Free Survival ◽

First Line Treatment

Abstract Background Vascular mimicry (VM) was associated with the prognosis of cancers. The aim of the study was to explore the association between VM and anticancer therapy response in patients with lung adenocarcinoma. Methods This was a single-center retrospective study of patients with lung adenocarcinoma between March 1st, 2013, to April 1st, 2019, at the Second People’s Hospital of Taizhou City. All included patients were divided into the VM and no-VM groups according to whether VM was observed or not in the specimen. Vessels with positive PAS and negative CD34 staining were confirmed as VM. The main outcome was progression-free survival (PFS). Results Sixty-six (50.4%) patients were male. Eighty-one patients received chemotherapy as the first-line treatment, and 50 patients received TKIs. Forty-five (34.4%) patients were confirmed with VM. There was no difference regarding the first-line treatment between the VM and no-VM groups (P = 0.285). The 86 patients without VM had a median PFS of 279 (range, 90–1095) days, and 45 patients with VM had a median PFS of 167 (range, 90–369) days (P < 0.001). T stage (hazard ratio (HR) = 1.37, 95% confidence interval (CI): 1.10–1.71), N stage (HR = 1.43, 95%CI: 1.09–1.86), M stage (HR = 2.85, 95%CI: 1.76–4.61), differentiation (HR = 1.85, 95%CI: 1.29–2.65), therapy (HR = 0.32, 95%CI: 0.21–0.49), VM (HR = 2.12, 95%CI: 1.33–3.37), and ECOG (HR = 1.41, 95%CI: 1.09–1.84) were independently associated with PFS. Conclusion The benefits of first-line TKIs for NSCLC with EGFR mutation are possibly better than those of platinum-based regimens in patients without VM, but there is no difference in the benefit of chemotherapy or target therapy for VM-positive NSCLC harboring EGFR mutations.

Download Full-text

Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the „good responder“?

10.1183/13993003.congress-2021.pa2306 ◽

2021 ◽

Author(s):

Kristian Brat ◽

Jana Skrickova ◽

Monika Bratova ◽

Magda Barinova ◽

Karolina Hurdalkova ◽

...

Keyword(s):

Prognostic Factor ◽

Lung Adenocarcinoma ◽

Treatment Success ◽

Progression Free Survival ◽

Line Treatment ◽

Good Responder ◽

First Line ◽

Free Survival ◽

First Line Treatment

Download Full-text

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

Cancers ◽

10.3390/cancers10110434 ◽

2018 ◽

Vol 10 (11) ◽

pp. 434 ◽

Cited By ~ 4

Author(s):

Ming-Ju Tsai ◽

Jen-Yu Hung ◽

Mei-Hsuan Lee ◽

Chia-Yu Kuo ◽

Yu-Chen Tsai ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Stage Iv ◽

Progression Free Survival ◽

Egfr Mutations ◽

First Line ◽

Free Survival ◽

Younger Patients ◽

Epidermal Growth

Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controversial. We, therefore, performed a retrospective study, screening 2958 patients. A total of 67 patients with lung adenocarcinoma harboring uncommon EGFR mutations were enrolled and 57 patients with stage IV diseases receiving a first-line EGFR TKI were included for further analyses. The patients were classified into 27 (47%) “a single sensitizing uncommon mutation”, 7 (12%) “multiple sensitizing mutations”, 5 (9%) “a sensitizing mutation and a resistant uncommon mutation”, and 18 (32%) “other resistant uncommon mutations”. No significant difference was noted in PFS or overall survival (OS) between groups. Patients receiving different first-line EGFR TKIs had similar PFS and OS. The elder patients had a significantly poorer performance status than the younger patients but a significantly longer PFS than the younger patients (median PFS: 10.5 vs. 5.5 months, p = 0.0320). In conclusion, this is the first study to identify that elderly patients with stage IV lung adenocarcinoma harboring uncommon EGFR mutation might have a longer PFS. Large-scale prospective studies are mandatory to prove our findings.

Download Full-text

Circulating Tumor Cells Counting Act as a Potential Prognostic Factor in Cervical Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533033820957005 ◽

2020 ◽

Vol 19 ◽

pp. 153303382095700 ◽

Cited By ~ 1

Author(s):

Kunpeng Du ◽

Qian Huang ◽

Junguo Bu ◽

Jieling Zhou ◽

Zijian Huang ◽

...

Keyword(s):

Cervical Cancer ◽

Prognostic Factor ◽

Progression Free Survival ◽

Disease Stage ◽

Histological Differentiation ◽

Free Survival ◽

Pathological Type ◽

Negative Prognostic Factor ◽

The Relationship ◽

Independent Negative Prognostic Factor

Background: Circulating tumor cells (CTCs) hold huge potential for both clinical applications and basic research into the management of cancer, but the relationship between CTC count and cervical cancer prognosis remains unclear. Therefore, research on this topic is urgently required. Objective: This study investigated whether CTCs were detectable in patients with cervical cancer and whether CTC count was an indicator of prognosis. Methods: We enrolled 107 patients with pathologically confirmed cervical cancer. CTCs were detected after radiotherapy or concurrent cisplatin-containing chemotherapy in all patients. We evaluated all medical records and imaging data as well as follow-up information to calculate progression-free survival (PFS). PFS was defined as the time until first diagnosis of tumor progression or death. We also analyzed the relationship between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Results: CTCs were identified in 86 of 107 patients (80%), and the CTC count ranged from 0 to 27 cells in 3.2 mL blood. The median progression-free survival (PFS) was 43.1 months. Patients in which CTCs were detected had a significantly shorter PFS than CTC-negative patients (P = 0.018). Multivariate analysis indicated that CTC count was an independent negative prognostic factor for survival. However, no correlation was observed between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Conclusion: CTC count is an independent negative prognostic factor for cervical cancer.

Download Full-text

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world setting

10.21203/rs.3.rs-1106177/v1 ◽

2021 ◽

Author(s):

Ming-Wei Chen Ming-Wei Chen ◽

An-Tai He . ◽

Yi Pei .

Keyword(s):

Lung Adenocarcinoma ◽

Survival Time ◽

Progression Free Survival ◽

Egfr Mutations ◽

Combination Group ◽

First Line ◽

Free Survival ◽

Mean Survival Time ◽

First Line Therapy ◽

To Receive

Abstract BackgroundTo explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations, a head-to-head study was performed to compare chemotherapy and gefitinib-erlotinip, osimertinib treatment in combination or with either agent alone as first-line therapy, in terms of efficacy and safety.MethodsA total of 200 untreated patients with advanced lung adenocarcinoma who harbored sensitive EGFR mutations were randomly assigned to receive gefitinib-erlotinip combined with pemetrexed and carboplatin group, gefitinib-erlotinip osimertinib combined with pemetrexed and carboplatin group, pemetrexed plus carboplatin alone group, or gefitinib-erlotinip alone group, osimertinib alone group.ResultsThe progression-free survival (PFS) of patients in the gefitinib-erlotinip combination group Mean Survival Time PFS 22.00 month,95%CI[16.29,27.70] and osimertinib gefitinib-erlotinip combination group Mean Survival Time PFS 40.00 month,95%CI[28.12,51.87]was longer than that of patients in the chemotherapy alone group PFS10,81 months, 95% CI,[ 8.99–12.64],gefitinib-erlotinip alone group PFS14.00 month.95%CI[11.98-20.01], osimertinib alone group PFS 26.66 month 95%CI[24.77-29.22].The gefitinib-erlotinip osimertinib combinational resulted in longer overall survival (OS) than chemotherapy alone (HR = 0.46, p = 0.016) or gefitinib-erlotinip alone (HR = 0.36, p = 0.01). osimertinib alone (HR = 0.26, p = 0.01).ConclusionsOur finding suggested that treatment with pemetrexed plus carboplatin combined with gefitinib-erlotinip and pemetrexed plus carboplatin combined with gefitinib-erlotinip osimertinib group could provide better survival benefits for patients with lung adenocarcinoma harboring sensitive EGFR mutations.

Download Full-text